Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec's wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL), received an order on March 10, 2026 from the Deputy Commissioner of State Tax, Maharashtra, in an appeal filed in May 2025. The original tax demand of ₹1.58 crore related to alleged excess or ineligible Input Tax Credit for FY2024-25 has been reduced to ₹0.81 crore under the new order. The company believes the remaining demand is not maintainable and plans to file a further appeal with the appellate authority. The company has stated that it does not foresee any material impact on its financial position, operations, or other activities.
The reduction of the tax demand from ₹1.58 crore to ₹0.81 crore is a positive development, halving the potential liability. However, with the company planning a further appeal, the matter remains unresolved and is a minor overhang, though the amount is small relative to typical corporate operations.